BeyondSpring Inc (BYSI) - Total Assets
Based on the latest financial reports, BeyondSpring Inc (BYSI) holds total assets worth $25.93 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check BeyondSpring Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
BeyondSpring Inc - Total Assets Trend (2014–2025)
This chart illustrates how BeyondSpring Inc's total assets have evolved over time, based on quarterly financial data. Check BeyondSpring Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
BeyondSpring Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
BeyondSpring Inc's total assets of $25.93 Million consist of 80.5% current assets and 19.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how BeyondSpring Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of BeyondSpring Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BeyondSpring Inc's current assets represent 80.5% of total assets in 2025, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 30.0% of total assets in 2025, down from 33.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
BeyondSpring Inc Competitors by Total Assets
Key competitors of BeyondSpring Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
BeyondSpring Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.54 | 2.60 | 7.47 |
| Quick Ratio | 1.54 | 2.60 | 7.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.31 Million | $17.57 Million | $81.74 Million |
BeyondSpring Inc - Advanced Valuation Insights
This section examines the relationship between BeyondSpring Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.38 |
| Latest Market Cap to Assets Ratio | 2.36 |
| Asset Growth Rate (YoY) | -24.4% |
| Total Assets | $25.93 Million |
| Market Capitalization | $61.27 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values BeyondSpring Inc's assets at a significant premium (2.36x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: BeyondSpring Inc's assets decreased by 24.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for BeyondSpring Inc (2014–2025)
The table below shows the annual total assets of BeyondSpring Inc from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $25.93 Million | -24.43% |
| 2024-12-31 | $34.31 Million | +38.32% |
| 2023-12-31 | $24.81 Million | -46.33% |
| 2022-12-31 | $46.22 Million | -43.39% |
| 2021-12-31 | $81.65 Million | -30.24% |
| 2020-12-31 | $117.04 Million | +162.68% |
| 2019-12-31 | $44.55 Million | +530.82% |
| 2018-12-31 | $7.06 Million | -78.48% |
| 2017-12-31 | $32.83 Million | +120.20% |
| 2016-12-31 | $14.91 Million | +35.90% |
| 2015-12-31 | $10.97 Million | +834.41% |
| 2014-12-31 | $1.17 Million | -- |
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical t… Read more